Really pleased to announce the publication of our latest bit of research
https://doi.org/10.1111/bju.14811
We have developed a urine test to diagnose aggressive prostate cancer and predict whether patients will require treatment up to five years earlier
than standard clinical methods. The experimental new test called ‘PUR’ (Prostate Urine Risk) also
identifies men who are up to eight times less likely to need treatment within
five years of diagnosis. It is hoped that the breakthrough could help large numbers of men
avoid an unnecessary initial biopsy and repeated invasive follow-ups for ‘low risk’ patients on active surveillance.
This work was funded by the Movember Foundation, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, the Andy Ripley Memorial Fund and the Stephen Hargrave Trust.
We've had quite a bit of press attention: